These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9408856)

  • 41. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization.
    Le Coz F; Funck-Brentano C; Morell T; Ghadanfar MM; Jaillon P
    Clin Pharmacol Ther; 1995 May; 57(5):533-42. PubMed ID: 7768076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lack of effect of mizolastine on the safety and pharmacokinetics of digoxin administered orally in repeated doses to healthy volunteers.
    Chaufour S; Le Coz F; Denolle T; Dubruc C; Cimarosti I; Deschamps C; Ulliac N; Delhotal-Landes B; Rosenzweig P
    Int J Clin Pharmacol Ther; 1998 May; 36(5):286-91. PubMed ID: 9629994
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
    Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
    Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Single- and multiple-dose mibefradil pharmacokinetics in normal and hypertensive subjects.
    Welker HA
    J Pharm Pharmacol; 1998 Sep; 50(9):983-7. PubMed ID: 9811158
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent.
    Benavides J; Schoemaker H; Dana C; Claustre Y; Delahaye M; Prouteau M; Manoury P; Allen J; Scatton B; Langer SZ
    Arzneimittelforschung; 1995 May; 45(5):551-8. PubMed ID: 7612054
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bilastine: a new H
    Church MK; Labeaga L
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1447-1452. PubMed ID: 28467671
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent.
    Levrier J; Duval D; Prouteau M; Voltz C; Berry CN; Lloyd KG; Scatton B
    Arzneimittelforschung; 1995 May; 45(5):559-68. PubMed ID: 7541995
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration.
    Huupponen R; Paija O; Salonen M; Björklund H; Rouru J; Anttila M
    Drugs R D; 2003; 4(6):339-45. PubMed ID: 14584962
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of a single dose of ofloxacin in healthy elderly subjects using noncompartmental and compartmental models.
    Rademaker CM; Jones RW; Notarianni LJ; van Dijk A; Glerum JH; Verhoef J
    Pharm Weekbl Sci; 1989 Dec; 11(6):224-8. PubMed ID: 2616254
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin.
    Mück W; Ritter W; Ochmann K; Unger S; Ahr G; Wingender W; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):255-60. PubMed ID: 9208342
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Astemizole: its pharmacokinetics and pharmacologic properties].
    Levron JC; Gillardin JM; Sabbah A
    Allerg Immunol (Paris); 1990 Jun; 22(6):233-41. PubMed ID: 1974137
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bioavailability and Pharmacokinetics of TRPV1 Antagonist Mavatrep (JNJ-39439335) Tablet and Capsule Formulations in Healthy Men: Two Open-Label, Crossover, Single-Dose Phase 1 Studies.
    Manitpisitkul P; Shalayda K; Russell L; Sanga P; Williams Y; Solanki B; Caruso J; Moyer JA
    Clin Pharmacol Drug Dev; 2018 Sep; 7(7):699-711. PubMed ID: 29125700
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of phenylethylmalonamide (PEMA) after oral and intravenous administration.
    Pisani F; Richens A
    Clin Pharmacokinet; 1983; 8(3):272-6. PubMed ID: 6851372
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transdermal administration of emedastine.
    Harada S; Takahashi Y; Nakagawa H
    Biol Pharm Bull; 1993 Sep; 16(9):884-8. PubMed ID: 7903575
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systemic bioavailability of nasally applied chlorphenamine maleate (0.4% nasal spray) relative to tablets administered perorally.
    Van Toor BS; Buchwald A; Stengele E; Trenk D; Gercek C; de Mey CM
    Int J Clin Pharmacol Ther; 2001 Apr; 39(4):173-8. PubMed ID: 11332874
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers.
    Kölle EU; Vollmer KO
    Br J Clin Pharmacol; 1986; 22 Suppl 2(Suppl 2):135S-141S. PubMed ID: 3620273
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics and pharmacodynamics of clemastine in healthy horses.
    Törneke K; Ingvast-Larsson C; Pettersson K; Bergvall K; Hedeland M; Bondesson U; Broström H
    J Vet Pharmacol Ther; 2003 Apr; 26(2):151-7. PubMed ID: 12667185
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations.
    Schran HF; Petryk L; Chang CT; O'Connor R; Gelbert MB
    J Clin Pharmacol; 1996 Oct; 36(10):911-22. PubMed ID: 8930778
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of luxabendazole after oral and intravenous administration to sheep.
    Ortiz AI; Alvarez-Bujidos L; Ferre I; Ordóñez D
    Am J Vet Res; 1997 Nov; 58(11):1263-6. PubMed ID: 9361890
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Haloperidol kinetics after oral and intravenous doses.
    Holley FO; Magliozzi JR; Stanski DR; Lombrozo L; Hollister LE
    Clin Pharmacol Ther; 1983 Apr; 33(4):477-84. PubMed ID: 6831826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.